Latest News and Press Releases

Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curveInitial data...

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the...

Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall...

CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial...

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation...

Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curveNegative or low PD-L1 status appears to be associated with long survival in CAN-2409 treated...

NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral...

Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel...